DNL747
DNLI-D-0002
Phase 1 small_molecule completed
Quick answer
DNL747 for Alzheimer Disease is a Phase 1 program (small_molecule) at Denali Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Denali Therapeutics
- Indication
- Alzheimer Disease
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed